NEW YORK, June 26, 2026, 08:04 (EDT)
- INVO Fertility jumped 51.6% to $1.8797 in premarket trading. Volume was 49 times higher than the 65-day average.
- The company bought out its Birmingham, Alabama clinic joint venture for $175,001, paying just $1 at closing.
- Nasdaq said INVO is now in compliance with its timely filing rule, after it filed its delayed 2025 and first-quarter reports.
- Shareholders are set to vote July 23 on a move that could let the company issue a lot more shares, with a proposal to raise authorized common stock to 250 million shares.
INVO Fertility, Inc. (NASDAQ:IVF) moved higher before the bell Friday after saying it had struck a low-cash deal to merge an Alabama clinic and announcing Nasdaq shut a compliance case related to its filings. U.S. exchanges were open for trading; Nasdaq’s holiday calendar for 2026 lists closures on June 19 and July 3, but not June 26.
Shares traded at $1.8797 as of 8:00 a.m. EDT, up 51.6% premarket from Thursday’s close of $1.24. Premarket volume had reached 19.5 million shares. That’s well over the 65-day average of 395,420 shares, FactSet data showed in the Wall Street Journal. Thursday saw volume jump to 7.1 million as the stock touched a 52-week low of $1.20.
Volume tells the story, not price. INVO disclosed 1.786 million common shares outstanding in its latest proxy filed June 18, so by 8:00 a.m. premarket, that many shares had traded nearly 11 times over. Shares were still down about 99% from the 52-week high of $169.60.
INVO Centers, a fully owned subsidiary, took full control of HRCFG, LLC, its JV partner at a Birmingham fertility clinic, according to a new filing. The deal is priced at $175,001: $1 in cash up front, $48,000 to be paid off in monthly installments from October, and $127,000 from HRCFG’s free cash flow. With this buy, the Birmingham clinic—one of INVO’s four—will be consolidated into INVO’s financials going forward.
That’s important since the deal uses little upfront cash but shifts how investors read the financials. INVO didn’t provide revenue or profit numbers for the Alabama JV in the 8-K.
Nasdaq staff on June 23 told INVO it had regained compliance with Listing Rule 5250(c)(1), according to the same filing. INVO filed its 2025 Form 10-K on June 2 and its first-quarter Form 10-Q on June 22. The company had received notices from Nasdaq in April and May over those late filings.
INVO shares jumped ahead of a key capital-structure vote. The July 23 annual meeting will ask holders to approve lifting authorized common stock to 250 million from 50 million, as well as issuing shares linked to inducement warrants, a 1 million-share stock incentive plan, and signing off on a potential equity deal that could top 20% of outstanding stock at below certain Nasdaq reference prices.
The proposed 250 million share authorization is roughly 140 times the 1.786 million common shares outstanding as of June 18. It doesn’t mean those shares will get issued, but the board would have flexibility for financing, warrants, equity compensation and deals.
INVO’s Q1 revenue came in at $2.02 million, up 23% from a year ago. Clinic revenue made up $1.98 million of the total. Net loss from continuing operations grew to $5.5 million from $1.5 million, with a $3.8 million non-cash warrant remeasurement hit. Operating cash use got better at $1.9 million. INVO ended the quarter with $4.9 million in cash.
CEO Steve Shum said in the June 22 earnings release that stockholders’ equity is now more than double what it was at year-end. He said the main priorities are to integrate and grow the current clinic base.
